Company Updates - *ST Jingfeng announced the resignation of director Yang Dong due to personal reasons, effective immediately, and he will no longer hold any position within the company [1] - The board of directors has approved the nomination of Lian Qizhi as a non-independent director candidate, who will also serve on the audit committee and the remuneration and assessment committee upon election [1] Financial Performance - For the first half of 2025, *ST Jingfeng's revenue composition is as follows: pharmaceuticals account for 93.8%, while other segments account for 6.2% [1]

Company Performance - *ST Jingfeng reported a revenue of approximately 272 million yuan for the first three quarters of 2023, representing a year-on-year decrease of 7.75% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 44.56 million yuan [1] - The basic earnings per share showed a loss of 0.0507 yuan [1] Market Context - As of the report, *ST Jingfeng's market capitalization stood at 7.1 billion yuan [2] - The A-share market has recently surpassed 4000 points, indicating a significant market resurgence after a decade of stagnation, with a new "slow bull" market pattern emerging [2]

Core Viewpoint - Hunan Jingfeng Pharmaceutical Co., Ltd. (*ST Jingfeng) has shown a reverse trend in performance improvement, with a net profit of 11.9975 million yuan in Q3 2025, representing a year-on-year increase of 23.91% [1] Group 1: Debt Restructuring and Financial Improvement - The orderly progress of the restructuring process has injected vital energy into *ST Jingfeng, significantly alleviating debt pressure [2] - The company has reached agreements with bondholders to effectively reduce financial costs, improving the quality of financial statements [2] - Capital injection and debt waivers have collectively supplemented working capital and optimized the asset-liability structure, creating conditions for the recovery of core business [2] Group 2: Asset Optimization and Cash Flow Improvement - *ST Jingfeng has optimized resource allocation through asset disposals, leading to a significant improvement in cash flow [3] - The company has implemented cost reduction and efficiency enhancement measures, improving the efficiency of fund utilization [3] - By divesting loss-making subsidiaries and focusing on core product lines, the company has laid a foundation for improved operational efficiency [3] Group 3: Market Expansion and R&D Support - The company's core products have achieved volume growth through successful bids in centralized procurement, becoming a key support for revenue growth [4] - The collaboration with Shijiazhuang Pharmaceutical Group is expected to activate the value of existing assets, providing a rebirth opportunity for *ST Jingfeng [4] - Short-term financial improvements are driving performance rebounds, while long-term sustainability will depend on the volume growth of core products and R&D conversion efficiency [4]

Financial Performance - The company's operating revenue for Q3 2025 was ¥88,468,069.36, a decrease of 3.97% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2025 was ¥11,997,449.39, representing an increase of 23.91% year-on-year[5]. - The net cash flow from operating activities increased by 32.02% to ¥30,237,660.00 for the year-to-date period[11]. - Total operating revenue decreased to ¥271,855,932.89 from ¥294,702,061.41, a decline of approximately 7.3% year-over-year[22]. - Net profit for the period was a loss of ¥43,275,302.08, compared to a loss of ¥49,537,995.02 in the previous period, showing an improvement of approximately 12.9%[24]. - The total comprehensive income for the period was a loss of ¥43,144,469.50, compared to a loss of ¥49,390,479.30 in the previous period, reflecting an improvement of approximately 12.5%[24]. Assets and Liabilities - The total assets at the end of the reporting period were ¥877,985,236.43, down 6.60% from the previous year-end[5]. - The company's total liabilities decreased to ¥915,740,332.36 from ¥955,113,140.50, a reduction of about 4.1%[20]. - The equity attributable to shareholders decreased by 54.40% to ¥37,298,014.96 compared to the previous year-end[5]. - The company's current liabilities totaled CNY 787,923,945.80, a decrease from CNY 904,732,064.73 at the beginning of the period[19]. - The company has outstanding principal of CNY 29,463.92 million on its "16 Jingfeng 01" bonds, which have not been repaid as of December 31, 2023[17]. Cash Flow and Financing - Cash and cash equivalents decreased to CNY 26,144,344.03 from CNY 85,523,763.96[18]. - Cash flow from operating activities generated ¥30,237,662.81, an increase from ¥22,904,392.10 in the previous period, representing a growth of approximately 32.3%[25]. - Total cash inflow from financing activities was $20,000,000.00, while cash outflow reached $152,753,968.54, resulting in a net cash flow of -$132,753,968.54[26]. - Cash outflow for debt repayment was $143,283,819.51, indicating a substantial commitment to servicing existing debt[26]. Restructuring and Legal Matters - The company has entered a restructuring process as of the report date, aiming to improve its asset-liability structure and operational status[16]. - The company has initiated pre-restructuring proceedings to enhance the feasibility of its restructuring plan[15]. - The company has appointed Beijing Zhonglun Law Firm as the administrator for its restructuring process[15]. - If the restructuring fails, the company faces the risk of bankruptcy and potential delisting of its shares[16]. - The company has ongoing issues with bond repayments, with ¥29,463.92 million still overdue as of December 31, 2023[6]. Accounting and Reporting - The company plans to adjust its financial statements to correct previous accounting errors, which may impact future reports[7]. - The company did not undergo an audit for the third quarter financial report[27]. - The financial report for the third quarter is unaudited, which may impact investor confidence[27]. - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[28]. Other Financial Metrics - The basic earnings per share improved by 24.02% to -0.0136 for Q3 2025 compared to the same period last year[5]. - Research and development expenses were ¥7,735,744.64, slightly down from ¥8,558,779.13, indicating a decrease of about 9.6% year-over-year[22]. - The company reported an investment income of ¥1,395,768.83, compared to a loss of ¥432,127.99 in the previous period, marking a significant turnaround[22]. - Basic and diluted earnings per share were both reported at -0.0507, an improvement from -0.0555 in the previous period[24]. - The company reported a non-recurring loss of ¥7,537,377.97 for the current reporting period[9].

证券代码：000908 证券简称：*ST 景峰 公告编号：2025-082 湖南景峰医药股份有限公司 关于公司董事变动的公告 湖南景峰医药股份有限公司（以下简称"公司"）董事会近日收到董事杨栋先生 提交的书面辞职信，杨栋先生因个人原因申请辞去公司第八届董事会董事、审计委 员会委员、薪酬与考核委员会委员职务，辞职后不再担任公司任何职务。截至本公 告披露日，杨栋先生未持有公司股份，不存在应当履行而未履行的承诺事项。 杨栋先生原定任期至第八届董事会换届之日止。根据《公司法》等相关规定， 杨栋先生的辞职不会导致公司董事会成员低于法定最低人数，不会影响公司董事会 的正常运作，其辞职报告自送达公司董事会之日起生效。 二、关于选举公司董事的相关情况 经公司第八届董事会提名委员会进行资格审查，公司董事会于 2025 年 10 月 27 日召开第八届董事会第四十三次会议，审议通过了《关于提名公司第八届董事会非 独立董事候选人的议案》，公司董事会同意提名廉奇志先生（简历附后）作为公司 第八届董事会非独立董事候选人，并同意廉奇志先生当选为非独立董事后，同时担 任公司第八届董事会审计委员会委员、薪酬与考核委员会委员，任期自股东大会审 ...

关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：000908 证券简称：*ST 景峰 公告编号：2025-083 湖南景峰医药股份有限公司 一、召开会议基本情况 1、股东大会届次：2025 年第二次临时股东大会。 2、股东大会的召集人：公司第八届董事会。董事会已审议通过了召开本次 股东大会的议案，本次股东大会的召开符合有关法律、行政法规、部门规章、规 范性文件和公司章程的规定。 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所 股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关 规定。 4、会议时间： （1）现场会议召开时间：2025 年 11 月 19 日 14:50 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 19 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为 2 ...

证券代码：000908 证券简称：*ST景峰 公告编号：2025-080 湖南景峰医药股份有限公司 第八届董事会第四十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、湖南景峰医药股份有限公司（以下简称"公司"）于2025年10月17日以电子 邮件、电话、即时通讯等方式发出了关于召开第八届董事会第四十三次会议的通知。 2、公司第八届董事会第四十三次会议于2025年10月27日上午9:00-11:00以通 讯方式召开。 3、会议应参加表决董事8人，实际参与表决董事8人。 4、会议由代行董事长张莉女士主持，公司监事及高级管理人员列席了会议。 5、本次会议的通知、召集、召开、审议、表决程序均符合法律、行政法规、部 门规章、规范性文件和《公司章程》的规定，会议形成的决议合法、有效。 二、董事会会议审议情况 具体内容详见公司同日在巨潮资讯网站披露的《2025年第三季度报告》（公告 编号：2025-081）。 表决结果：8票同意，0票反对，0票弃权。 2、《关于提名公司第八届董事会非独立董事候选人的议案》； 经公司董事会提名委员 ...

湖南景峰医药股份有限公司 股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 1、湖南景峰医药股份有限公司（以下简称"公司"）于 2025 年 10 月 21 日收到湖南省常德市中级人民法院（以下简称"常德中院"）送达的（2024） 湘 07 破申 7 号《民事裁定书》和（2025）湘 07 破 15 号《决定书》，裁定受 理彭东钜、上海鑫绰投资管理有限公司对公司的重整申请，并指定北京市中伦 律师事务所担任公司管理人。 2、常德中院已裁定公司进入重整程序，公司可能存在因重整失败而被宣 告破产的风险。如果法院裁定公司破产，公司将被实施破产清算，根据《深圳 证券交易所股票上市规则》（以下简称《股票上市规则》）第 9.4.18 条第 （八）项的规定，公司股票将面临被终止上市的风险。 证券代码：000908 证券简称：*ST 景峰 公告编号：2025-084 3、公司最近三个会计年度扣除非经常性损益前后净利润孰低者均为负值， 同时，大信会计师事务所（特殊普通合伙）（以下简称"大信"）对公司 2024 年度财务报告出具了带持续经营相关 ...

2025 年 10 月 27 日，公司收到湖南省常德市中级人民法院（以下简称"常德中 院"或者"法院"）送达的《决定书》[（2025）湘 07 破 15 号之一]，准许公司在 管理人的监督下自行管理财产和营业事务。根据《股票上市规则》及《深圳证券交 易所上市公司自律监管指引第 14 号——破产重整等事项》等相关规定，现将相关情 况公告如下： 一、《决定书》主要内容 2025 年 10 月 23 日，景峰医药向法院提出申请，请求法院许可其在重整期间在 管理人监督下自行管理财产和营业事务。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 湖南景峰医药股份有限公司（以下简称"景峰医药"或者"公司"）重整工作 正有序推进中，如公司顺利实施重整并执行完毕重整计划，将有利于化解债务风险， 有利于优化公司资产负债结构，提升公司的持续经营和盈利能力。如果公司未能顺 利实施重整或执行完毕重整计划，公司仍存在因重整失败而被宣告破产的风险。如 果公司被宣告破产，根据《深圳证券交易所股票上市规则》（以下简称《股票上市 规则》）的相关规定，公司股票将面临被终止上市的风险。 ...

关于法院许可公司在重整期间继续营业的公告 证券代码：000908 证券简称：*ST景峰 公告编号：2025-079 湖南景峰医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 2、公司 2022 年度、2023 年度及 2024 年度扣除非经常性损益前后净利润孰低者 均为负值，同时，大信会计师事务所（特殊普通合伙）对公司 2024 年度财务报告出 具了带持续经营相关重大不确定性段落的无保留意见审计报告，公司存在触及《股 票上市规则》第 9.8.1 条第（七）项规定的被实施其他风险警示的情形，截至本公 告披露日，《2024 年年度审计报告》中"与持续经营相关的重大不确定性"段落涉 及事项的影响暂未消除。 根据《股票上市规则》的相关规定，法院已裁定受理申请人提出的重整申请， 公司股票交易已被深圳证券交易所实施退市风险警示。 3、如果公司顺利实施重整并执行完毕重整计划，将有利于改善公司的资产负债 结构，推动公司回归可持续发展轨道。若重整失败，公司将存在被法院裁定破产的 风险。如果公司被法院裁定破产，根据《股票上市规则》的相关规定，公司股票将 ...